Scientific Advisory Board

Benjamin Chain, Ph.D.

Prof. Chain has a B.A. in Natural Sciences and a Ph.D. in Zoology from the University of Cambridge. Professor Chain obtained his postdoctoral training at the Sloan Kettering Institute in New York and in the Department of Zoology at University College. Before assuming his present position as Professor of Immunology at University College London, Professor Chain held the positions of Senior Lecturer, Department of Biology and then Immunology and Reader in Immunology, Department of Immunology, both at University College, London.

Cheryl Fitzer-Attas, Ph.D.

Dr. Fitzer-Attas has been a member of the Scientific Advisory Board since its formation in April 2006. Currently, Dr. Fitzer-Attas is Associate Director of Scientific Affairs in the Global Marketing Division for Teva Pharmaceutical Industries, Ltd. After leaving academia in 1998, Dr. Fitzer-Attas has held varied positions in the biotechnology and pharmaceutical sectors including Senior Scientist at Bio-Technology General (Israel) Ltd. (now Savient Pharmaceuticals, Inc.) from 1998 to 2001, and Director of Biological Research promoted later to Vice President Research & Development at Mindset BioPharmaceuticals Ltd. from 2001 to 2004. Dr. Fitzer-Attas received her Ph.D. in Biology from the Weizmann Institute of Science.

Zelig Eshhar, Ph.D.

Prof. Eshhar obtained his B.Sc. in Biochemistry and Microbiology and his M.Sc. in Biochemistry from the Hebrew University, and his Ph.D. in the Department of Immunology from the Weizmann Institute of Science. He was a Research Fellow in the Department of Pathology at Harvard Medical School and in the Department of Chemical Immunology at the Weizmann Institute in Israel. Prof. Eshhar has held several positions at the Weizmann Institute, most recently Chairman of the Department of Immunology. Prof. Eshhar serves on several editorial boards, including Cancer Gene Therapy, Human Gene Therapy, Gene Therapy, Expert Opinion on Therapeutics, European Journal of Immunology and the Journal of Gene Medicine.

Alfred L. Goldberg, Ph.D.

Prof. Goldberg obtained his Ph.D. in Physiology at Harvard University. He has held academic positions in numerous institutes, including Harvard Medical School, Radcliffe College, University of California-Berkeley, Institute Pasteur and University of Paris. Prof. Goldberg served on numerous advisory boards of companies, including Biogen, Tanox, ProScript, Mindset BioPharmaceuticals, Point Therapeutics and the Michael J. Fox Foundation. He has served on many editorial boards, including the Journal of Biological Chemistry, the New England Journal of Medicine and Basic and Applied Myology.

Donald L. Price, M.D.

Prof. Price obtained a B.A. in English Literature from Wesleyan University and an M.D. from Albany Medical School, Union University. He was Assistant Professor of Pathology at Harvard Medical School, Director Neuropathology Laboratory at Boston City Hospital and Director of the Division of Neuropathology and Associate Professor of the Departments of Pathology and Neurology at the Johns Hopkins Medical Institute. Since 1978, Prof. Price has been Professor of the Departments of Pathology Neurology and Neuroscience at Johns Hopkins, where he was the founding director of the Alzheimer's Disease Research Center.

Clinical Advisory Board

Paul Bendheim, M.D.
Chairman

Dr. Bendheim obtained his B.A. from Pomona College, Claremont, and his M.D. degree from the University of Arizona College of Medicine. He held various positions at the Laboratory of Transmissible Neurodegenerative Diseases and the Geriatric Neurology Clinic. Dr. Bendheim was a Visiting Professor in the Department of Neurobiology at the Weizmann Institute of Science, Medical Director of the Copaxone Division at Teva Pharmaceuticals, and Executive Vice President & Chief Medical Officer of Mindset Biopharmaceuticals. Dr. Bendheim is the Medical Director of Development and a research neurologist of the AD Institute of the Banner Good Samaritan Medical Center, in Phoenix, Arizona and is the Founder and Chairman of BrainSavers, a company that has developed a program to maintain and improve brain function as individuals age.

Steven H. Ferris, Ph.D.

Prof. Ferris obtained his B.A. in Psychology at Rensselaer Polytechnic Institute, his M.A. in Psychology at Queens College and his Ph.D. in Experimental Psychology at the City University of NY. He has held several academic appointments in the department of Psychiatry at the NYU School of Medicine, where he is the Gerald J. & Dorothy R. Friedman Prof. of the NYU AD Center. He is the Executive Director of the Aging and Dementia Research Center and the Director of the National Institutes on Aging AD Center at the NYU School of Medicine. He is currently directing a national, NIH consortium study designed to improve the efficiency of primary prevention trials for AD.

Douglas R. Galasko, M,D.

Prof. Galasko is a member of the Department of Neurosciences at the School of Medicine, Univeristy of California,SD. His specific areas of investigation include biological markers and genetic risk factors for Alzheimer's Disease (AD), heterogeneity in AD, and subtypes and variants. He is an Investigator at the UCSD Shiley-Marcos Alzheimer's Disease Research Center and developed the assessment instrument for activities of daily living (ADL) as part of an Alzheimer's Disease Cooperative Study (ADCS) instrument development protocol.

Eric Reiman, M.D.

Dr. Reiman attended medical school at Duke University and did his residency at Duke and Washington University. He is the Director, Alzheimer's Disease Research Program & Scientific Director, PET Center, Banner Good Samaritan Medical Center; Clinical Director, Neurogenomics Program, Translational Genomics Research Institute (TGen) and Professor and Associate Head for Research and Development (Phoenix Campus), Department of Psychiatry, The University of Arizona.

Thomas M. Wisniewski, M.D.

Dr. Wisniewski obtained his M.D. from Kings College School of Medicine in the UK. He did his Neurology and Neuropathology Residencies at New York University and Columbia-Presbyterian, respectively. Dr. Wisniewski is Professor of Neurology, Pathology and Psychiatry at New York University Medical Center and is a board certified Neurologist and Neuropathologist, he is also the Director of the Memory and Dementia Disorders Center and the Director of the Neuropathology Core of the NYU Alzheimer's Disease Center. Dr. Wisniewski has an active research laboratory focusing on neurodegenerative disorders, in particular the mechanisms which drive amyloid deposition in Alzheimer's and prion related diseases. This work has lead to over 150 peer-reviewed publications.